ArticleInternational journal of rheumatic diseases2022
Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
Article in International journal of rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- COVID-19 vaccine acceptance and hesitancy in Indian context: a systematic review and meta-analysis.Pathogens and global health · 2024Pooled it
- Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.European journal of medical research · 2024Pooled it
- Article
- Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.Annals of the rheumatic diseases · 2024Article
- Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.Rheumatology international · 2024Article
- Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases.Journal of family medicine and primary care · 2024Article
- Clinical and immunological responses to COVID-19 vaccination in rheumatoid arthritis patients on disease modifying antirheumatic drugs: a cross-sectional study.Journal of rheumatic diseases · 2024Article
- Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey.Rheumatology international · 2024Article
- Understanding Stakeholders' Perspectives to Increase COVID-19 Vaccine and Booster Uptake Among Black Individuals With Rheumatic Conditions.Arthritis care & research · 2023Article
- Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis.Vaccines · 2023Review
- Symptom flares after COVID-19 infection versus vaccination among youth with PANS/PANDAS.Allergy and asthma proceedings · 2023Article
- COVID-19 Vaccination Hesitancy in Autoimmune Disease Patients: Policy Action and Ethical Considerations.Vaccines · 2023Review
- Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.Rheumatology (Oxford, England) · 2023Article
- The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study.Rheumatology international · 2023Article
- COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs.RMD open · 2023Article
- Molecular Mimicry and HLA Polymorphisms May Drive Autoimmunity in Recipients of the BNT-162b2 mRNA Vaccine: A Computational Analysis.Microorganisms · 2023Article
- Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital.Therapeutic advances in vaccines and immunotherapy · 2023Article
- Understanding COVID-19 vaccine hesitancy in vasculitis patients.Frontiers in public health · 2023Article
- Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.International journal of rheumatic diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis survey was conducted to evaluate COVID-19 vaccination status in patients with autoimmune rheumatic diseases (AIRDs). Our objectives were to study vaccine hesitancy, adverse effects, breakthrough infections and flare of underlying disease in this population subgroup.
methodsThis was a multi-center, cross-sectional, interview-based survey done at 6 tertiary care centers across Tamil Nadu, in the southern part of India from September 15, 2021 to October 14, 2021. The survey questionnaire was filled up by AIRD patients attending their clinics. The survey questionnaire comprised a set of 14 questions, distributed between patient characteristics, vaccines taken, their characteristics and COVID-19 infection.
resultsThere were 2092 participants, with a mean age of 47.5 ± 13.17 years. Among them, 1293 (61.81%) were vaccinated, of which 837 (64.73%) were fully vaccinated. Two-thirds of our subjects were vaccinated with ChAdOx1 nCov-19 (COVISHIELD) (77.64%) and 21.57% with BBV 152 (COVAXIN). Age, gender, education and comorbidities had no association with vaccine hesitancy. The commonest (421; 52.69%) reason for vaccine hesitancy was fear of side effects. The incidence (n = 72) of breakthrough infections was similar in both the vaccine groups, of which 58 (80.55%) were partially vaccinated and 14 (19.44%) were fully vaccinated. Thirty-two patients had a flare of pre-existing rheumatic disease.
conclusionChAdOx1 nCov-19 and BBV 152 were found to be safe in patients with rheumatic diseases. Fear of side effects was the major cause of vaccine hesitancy. All adverse effects were minor and self-limiting. Breakthrough infections and disease flares occurred only in a small subset of our cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.